# PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

> **NCT03079011** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 1017 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib 125mg
- **DRUG:** Aromatase Inhibitors
- **DRUG:** Fulvestrant Injectable Product

## Key facts

- **NCT ID:** NCT03079011
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-22
- **Primary completion:** 2021-04-30
- **Final completion:** 2025-09-22
- **Target enrollment:** 1017 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079011, "PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03079011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*